Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 in Type 2 Diabetes Mellitus
CTR20220346Phase 2Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing HTD1801 with Placebo (2 arms). Primary endpoint: Change in glycated hemoglobin (HbA1c). Started Feb 2022; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20220346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220346.